drugset / Trial / NCT03921021
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Phase 2
Completed
17 enrolled
Weill Medical College of Cornell University
Oncolys BioPharma Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study of OBP-301 with pembrolizumab in advanced gastric and gastroesophageal junction adenocarcinoma that has progressed on at least 2 lines of prior therapy for advanced disease.
Timeline
- Start
- 2019-05-09
- Primary completion
- 2023-06-20
- Completion
- 2023-07-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | suratadenoturev | Unknown | 2e+12 vg | Other |